1984PubMedRequires access

[Possibilities for optimizing therapy with theophylline preparations. I. On the pharmacokinetics of theophylline preparations].

B Wiesner, Ingrid Sehrt, H Iwainsky

Open publisher page 0 citations

Abstract

In the treatment of obstructive lung diseases theophylline is one of the most important drugs. But its therapeutic range is narrow, therefore attempts are made for an optimal therapy (dosage adjusted to the theophylline concentration in the serum, treatment with microcrystalline theophylline or retard preparations). Pharmacokinetic studies are undertaken with two theophylline formulations commercially available and the commonly used aminophylline to achieve the optimal therapeutic benefit. Regarding the results Aminophylline retard belongs to the formulations with diminished bioavailability and is therefore not satisfactorily qualified for an optimal treatment. On the other hand the development of a formulation of microcrystalline theophylline like Bronkodyl promises advantages for the long-continued treatment of obstructive lung diseases because of the smaller differences of the individual pharmacokinetic values from the median values.

About this research paper

What this paper is about

In the treatment of obstructive lung diseases theophylline is one of the most important drugs. But its therapeutic range is narrow, therefore attempts are made for an optimal therapy (dosage adjusted to the theophylline concentration in the serum, treatment with microcrystalline theophylline or retard preparations). Pharmacokinetic studies are undertaken with two theophylline formulations commercially available and the commonly used aminophylline to achieve the optimal therapeutic benefit. Regarding the results Aminophylline retard belongs to the formulations with diminished bioavailability and is therefore not satisfactorily qualified for an optimal treatment. On the other hand the development of a formulation of microcrystalline theophylline like Bronkodyl promises advantages for the long-continued treatment of obstructive lung diseases because of the smaller differences of the individual pharmacokinetic values from the median values.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

In the treatment of obstructive lung diseases theophylline is one of the most important drugs. But its therapeutic range is narrow, therefore attempts are made for an optimal therapy (dosage adjusted to the theophylline concentration in the serum, treatment with microcrystalline theophylline or retard preparations). Pharmacokinetic studies are undertaken with two theophylline formulations commercially available and the commonly used aminophylline to achieve the optimal therapeutic benefit. Regarding the results Aminophylline retard belongs to the formulations with diminished bioavailability and is therefore not satisfactorily qualified for an optimal treatment. On the other hand the development of a formulation of microcrystalline theophylline like Bronkodyl promises advantages for the long-continued treatment of obstructive lung diseases because of the smaller differences of the individual pharmacokinetic values from the median values.

Key concepts: Theophylline, Aminophylline, Pharmacokinetics, Bioavailability, Therapeutic index, Bronchodilator, Medicine, Pharmacology

Related papers

Back to paper searchBrowse research topicsOriginal source
[Possibilities for optimizing therapy with theophylline preparations. I. On the pharmacokinetics of theophylline preparations]. — Research Paper | ScholarLens